TherapeuticsMD, Inc. Income Statement
TXMD|14 years of annual SEC 10-K data (FY2011-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
TherapeuticsMD, Inc. reported $1M in revenue and $10M in net loss for FY2024. Revenue has declined at a 3.6% compound annual rate over the past 13 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $70.0M | $2.6M | $49.6M | $16.1M | $16.8M | $19.4M | $20.1M | $15.0M | $8.8M | $3.8M | $2.1M | $2.1M | $2.1M |
| Cost of Revenue | - | $1.4M | $1.4M | $6.3M | $2.7M | $2.6M | $4.2M | $4.5M | $3.7M | $2.0M | $1.3M | $947.1K | $947.1K | $947.1K |
| Gross Profit | - | $68.6M | $1.2M | $43.3M | $13.4M | $14.1M | $15.2M | $15.6M | $11.4M | $6.8M | $2.5M | $1.1M | $1.1M | $1.1M |
| SG&A Expense | $8.9M | $56.7M | $80.7M | $60.5M | $116.0M | $57.7M | $51.3M | $28.7M | $22.1M | $19.0M | $14.1M | $6.4M | $6.4M | $6.4M |
| R&D Expense | - | - | - | $19.8M | $27.3M | $33.9M | $53.9M | $72.0M | $43.2M | $13.6M | $4.5M | $107.2K | $107.2K | $107.2K |
| Operating Income | -$8.5M | $1.2M | -$79.6M | -$151.2M | -$130.2M | -$77.6M | -$90.3M | -$85.2M | -$54.0M | -$25.8M | -$16.1M | -$5.4M | -$5.4M | -$5.4M |
| Interest Expense | $166.6K | $200.0K | $32.9M | $17.4M | $4.7M | $4.7M | - | - | - | - | $64.4K | $64.4K | $35.7K | $64.4K |
| Income Tax | -$43.0K | -$43.0K | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -$10.3M | $112.0M | -$172.4M | -$176.1M | -$132.6M | -$76.9M | -$89.9M | -$85.1M | -$54.2M | -$28.4M | -$35.1M | -$12.9M | -$12.9M | -$2.9M |
| EPS (Basic) | -$0.99 | $12.41 | -$21.66 | - | - | - | - | - | - | - | - | - | - | - |
| EPS (Diluted) | -$0.99 | $11.96 | -$21.66 | -$0.72 | -$0.59 | -$0.37 | -$0.46 | -$0.49 | -$0.36 | -$0.22 | -$0.38 | -$0.21 | -$0.21 | -$0.21 |
| Shares Outstanding | 11.5M | 9.5M | 8.6M | 299.8M | 271.2M | 240.5M | 216.4M | 196.7M | 177.9M | 145.0M | 145.0M | 16.6M | 55.5M | 83.0M |
| Gross Margin | - | 98.0% | 45.5% | 87.2% | 83.0% | 84.3% | 78.4% | 77.6% | 75.6% | 77.7% | 64.7% | 54.6% | 54.6% | 54.6% |
| Operating Margin | -654.6% | 1.7% | -3092.8% | -304.6% | -808.9% | -462.7% | -466.3% | -422.9% | -359.6% | -294.1% | -422.9% | -259.9% | -259.9% | -259.9% |
| Profit Margin | -789.4% | 160.1% | -6700.9% | -354.8% | -823.7% | -458.5% | -464.3% | -422.4% | -360.8% | -323.8% | -919.9% | -618.4% | -618.4% | -137.3% |